WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Breast Cancer Endpoints - Master Primary m9, Neoadjuvant setting has_component Overall Survival (OS), Effusion/ascites has_value >Yes >No, Tumor Biopsy has_pertinent _information Genomics/ Proteomics, FDA Criteria for Efficacy endpoints for Breast Cancer treatment has_pertinent_information Tumor Biopsy, Measurable lesions has_location Anatomical region, Lymph node examination measured_over Quantity of nodes, Adjuvant setting has_component Disease free survival (DFS), Disease present is measured from Breast tumor microscopic assessment, New disease/lesions is_classified_by >Local >Regional >Distant, Follow-up evaluation has_timepoint Date of progression, Tumor assessment is_derived_from RECIST v1.1 criteria, FDA Criteria for Efficacy endpoints for Breast Cancer treatment has_pertinent_information Cancer stage, Baseline assessment has_timepoint Date of evaluation, Neoadjuvant setting has_component Pathologic complete response (pCR), Target lesion has_component Quantitative assessment, Demographics/ Medical history has_components >Age >Ethnicity >Pregnancy status >BRCA1/2 mutation >Co-morbidities, Cystic lesion has_value >Simple >Complex, Concepts (e.g. Disease progression) are denoted by solid round-edged rectangle, Baseline assessment has_pertinent_ information Imaging evaluation method, Lymph node examination include_evaluation_of Size of largest lymph node metasteses